MuStDO 5 is a multivalent plasmid DNA vaccine for malaria comprised of five plasmid DNAs encoding five proteins from Plasmodium falciparum and one plasmid DNA encoding human GM-CSF. To evaluate the safety of MuStDO 5, a series of pre-clinical studies were conducted in mice and rabbits. In pharmacology studies in mice, GM-CSF could not be detected in the serum following either intramuscular or a combined intramuscular/intradermal administration of the vaccine, but was readily detected in the muscle following
Introduction
Malaria is one of the leading causes of disease and death from the Tropic of Cancer to the Tropic of Capricorn and represents a major health problem in more than 90 countries. An estimated 500 million cases of malaria occur each year with an estimated annual mortality rate of 1.5 to 2.7 million, predominately amongst children under the age of 5, but also with significant impact on pregnant women. 1, 2 Thus, an effective vaccine against malaria is needed. The effort to develop a vaccine for malaria has been difficult due, in large part, to the complex life cycle of the malaria parasite, with each stage being morphologically and antigenically distinct. 3 Complete protection has been achieved in animals and humans by immunization with live, irradiation-attenuated sporozoites, the mosquito-borne stage of the malaria parasite. 4 However, this type of vaccine is impractical for widespread use.
Due to the complex nature of the malaria parasite's life cycle, the ideal vaccine candidate would engender protective immunity against all phases of the life cycle and would be comprised of multiple antigens capable of inducing immune responses against multiple targets. With this in mind, a nucleic acid-based vaccine offers a promising approach because it provides for the expression of multiple antigens in vivo. Moreover, genetic intramuscular administration. In a tissue distribution study in mice, MuStDO 5 plasmid DNA was detected by PCR initially in highly vascularized tissues, while at later time-points the plasmid DNA was detected primarily at the site(s) of injection. In GLP safety studies in mice and rabbits, repeated intramuscular/intradermal administration of the MuStDO 5 vaccine was found to be safe and well tolerated without any evidence of autoimmune pathology. Gene Therapy (2001) 8, 1011-1023.
vaccination with plasmid DNA (pDNA) results in protective immunity in many species against viral, [5] [6] [7] [8] [9] [10] [11] bacterial, [12] [13] [14] and parasitic diseases, 15 including malaria. 16 Toward the goal of developing an effective genetic malaria vaccine, a phase I trial was recently completed in healthy volunteers using a pDNA vaccine encoding the malaria circumsporozoite protein from Plasmodium falciparum (PfCSP), the causative agent of malaria. Although the final goal is to develop a multi-component, protective, pDNA-based vaccine, this single antigen, monovalent vaccine, was first tested alone in a phase I clinical trial to demonstrate its safety and immunogenicity.
This dose-escalation trial used a regimen of three intramuscular injections at 1-month intervals at pDNA doses of 20, 100, 500 and 2500 g. The vaccine was found to be safe and well tolerated without any serious or adverse events and no clinically significant or hematological changes were observed. 17 Moreover, vaccination resulted in the induction of antigen-specific, genetically restricted, CD8
+ cytotoxic T lymphocytes (CTL), providing the first demonstration in healthy human volunteers of the induction of CD8
+ CTL responses using a pDNA-based genetic vaccine. 18 Based on these encouraging results, a multivalent pDNA-based vaccine was developed composed of five proteins from various stages of the P. falciparum life cycle.
The studies presented herein describe the results from a detailed and systematic preclinical evaluation of a multivalent malaria vaccine, MuStDO 5, comprised of five plasmid DNAs encoding malaria proteins from P. falciparum: circumsporozoite protein (PfCSP), sporozoite surface protein-2 (PfSSP2), exported protein-1 (PfEXP1), liver stage antigen-1 (PfLSA1), and liver stage antigen-3 (PfLSA3), and a sixth pDNA encoding human granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF, a potent growth factor for stem cells of the granulocyte and macrophage lineage, was included in the vaccine to enhance immunogenicity, as it is known to recruit dendritic cells to the site of administration and to promote the maturation of dendritic cell precursors which play an important role in presenting antigen to the immune system. [19] [20] [21] [22] [23] [24] Recently, the co-administration of GM-CSF encoding pDNA along with antigen encoding pDNA has been demonstrated to enhance immunogenicity in several pre-clinical animal models. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] Specifically, this approach has also been shown to increase protective immunity in the P. yoelii murine model of malaria. 36 Before clinical evaluation, the MuStDO 5 vaccine had to be carefully evaluated for pharmacology and safety. Consequently, a pharmacology study was conducted in mice to evaluate the pharmacokinetics of expression of GM-CSF in both serum and muscle following vaccine administration. The fate of the pDNA components of the MuStDO 5 vaccine was evaluated in a tissue distribution study in mice by PCR analysis at various time points from 48 h to 8 weeks after administration. Finally, the safety and toxicity of the MuStDO 5 vaccine was evaluated in mice and rabbits in studies conducted in compliance with United States Good Laboratory Practice Regulations (GLP). These studies were conducted in support of a phase I/II clinical trial in healthy volunteers in which the MuStDO 5 pDNA vaccine will be evaluated for safety, immunogenicity, and protection from challenge with live P. falciparum.
Results

mGM-CSF pharmacology in mice
To evaluate the serum expression of GM-CSF following vaccination with the MuStDO 5 vaccine, a 90-day non-GLP pharmacology study was conducted in mice. Due to the species-specificity of GM-CSF, and the need to evaluate the potential for an immune response against a selfcytokine, a pDNA encoding murine GM-CSF (mGM-CSF) was used in this study. In a treatment regimen analogous to that used for the GLP Repeat Dose Mouse Study (described later), mice received eight repeat (i.m./i.d.) injections of the MuStDO vaccine (20 g of each malaria pDNA plus 20 g mGM-CSF pDNA), twice a week for 4 consecutive weeks followed by a 9-week treatment-free period. Serum was evaluated at approximately 2-week intervals for mGM-CSF and for anti-mGM-CSF antibodies on days 27 and 89.
Murine GM-CSF could not be detected by ELISA in any of the serum samples at any time-point throughout the 90-day study. Antibodies to mGM-CSF were not found in the serum of mice at day 27 or day 89 (data not shown), indicating that the repeat i.m./i.d. administration of a pDNA encoding an endogenous cytokine did not result in the development of an aberrant autoimmune response to a self-protein.
Murine GM-CSF could not be detected in the serum following repeat intramuscular/intradermal (i.m./i.d.)
injections, yet the co-administration of GM-CSF pDNA with pDNA vaccines has been demonstrated to enhance immunogenicity, indicating that a biologically active protein is expressed following pDNA-mediated delivery. Accordingly, a second mGM-CSF pharmacology study was conducted to determine whether mGM-CSF could be detected in the injected muscles of mice. In this study, mice received a single i.m. injection of the MuSTDO vaccine (20 g of each malaria pDNA plus 20 g mGM-CSF pDNA). Control groups received either a single i.m. injection of 20 g mGM-CSF pDNA + 100 g of non-coding control vector, a single i.m. injection of 20 g of mGM-CSF pDNA alone, or a single i.m. injection of the MuSTDO vaccine without mGM-CSF pDNA (20 g of each malaria pDNA) + 20 g of control pDNA. Serum and the injected muscles were then assayed for mGM-CSF by ELISA at various times after administration.
Murine GM-CSF was readily detected in the muscle samples from mice which had received the MuStDO 5-mGM-CSF vaccine, mGM-CSF pDNA + control pDNA, or mGM-CSF pDNA alone (Figure 1a-c) , but was not detected in the serum of any animals or in the muscles of animals which had received MuStDO 5 (without mGM-CSF pDNA) + control pDNA (data not shown). For the mice injected with the MuSTDO5-mGM-CSF vaccine, mGM-CSF was detected as early as 6 h after administration, but could no longer be detected by day 14 after administration with a half-life of 1.2 days (Figure 1a) .
Mice which received either mGM-CSF pDNA + control pDNA or mGM-CSF pDNA alone had similar mGM-CSF muscle pharmacokinetics at the early time-points (6 h-10 days) as those that had received the MuStDO 5-mGM-CSF vaccine (Figure 1b, c) . However, in contrast to the MuStDO 5-mGM-CSF vaccine-treated group, mGM-CSF expression in the latter groups persisted to day 28 after administration with a half-life of 6.5 days for the mGM-CSF pDNA + control pDNA group and 6.9 days for mGM-CSF pDNA alone group. These results suggest that injection of a pDNA encoding a self protein such as mGM-CSF can lead to stable expression. In contrast, injection of pDNA encoding a foreign protein, such as a malaria protein, combined with pDNA encoding mGM-CSF, leads to short-term expression of mGM-CSF, possibly due to immune responses generated against the foreign proteins which non-specifically eliminate the mGM-CSF plasmid in those cells co-expressing the foreign protein plus mGM-CSF.
Tissue distribution in mice
To determine the fate of the MuStDO 5 vaccine, a quantitative tissue distribution study employing real-time Taqman PCR analysis was conducted in mice following a single i.m./i.d. injection of MuStDO 5 comprised of 10 g of each malaria pDNA plus 10 g of hGM-CSF pDNA. The i.m./i.d. route was evaluated because it represented the intended clinical route of administration at the time, and a pDNA encoding hGM-CSF was evaluated as it is the intended clinical vaccine. PCR primers used in this study were designed to amplify regions common to all of the plasmids in the vaccine. All PCR assays were found to be free of contamination as determined by the absence of any amplification products in the 'no DNA' control samples that were included in each set of PCR reactions (data not shown).
Plasmid DNA could not be detected in any of the tissues from the vehicle control-treated animals at any time-point with the exception of one blood sample in one of the control females at the 7-day time-point (45 copies, data not shown). It was presumed that this result was generated by cross-contamination of the sample during analysis or at the time of necropsy as all of the blood samples were extracted at the same time. In the vaccinetreated animals, pDNA was detected in all of the tissues with the exception of the gonads 48 h after administration with the highest level of plasmid detected at the sites of injection ( Table 1 ). The lower values observed in some of the dermis samples were a result of the inhibition of PCR assay occasionally observed with this tissue in this study. Plasmid DNA was detected at much lower levels in the peripheral tissues. The signals detected in the peripheral tissues at this early time-point may not represent actual uptake and retention of the pDNA, but rather plasmid present in the blood as the animals were not perfused before taking the tissue samples. It was not considered to be important at the early time-points to resolve specific uptake versus pDNA present in the circulation.
By 7 days after administration, pDNA was detected in all of the muscle samples and a majority of the dermis samples. Only three of the dermis samples yielded a reliable PCR reaction as the majority of the samples produced non-informative results due to the failure of the corresponding spiked samples to amplify. pDNA was also detected in the blood and peripheral tissues, but at a much lower level. By the later time-points, pDNA was cleared from most peripheral tissues and was present predominately at the site(s) of injection. The amount of pDNA in the dermis tissue could not be quantified at the 8-week time-point due to inhibition of the PCR assay. No obvious difference in the biodistribution pattern was observed between the dosed males and dosed females in the time-points studied.
Repeat dose safety studies in mice and rabbits To evaluate the toxicity of the MuStDO 5 vaccine, repeat dose safety studies were conducted in mice and rabbits following i.m./i.d. administration. In the mouse safety study, a plasmid DNA encoding murine GM-CSF was used to evaluate any potential biological and/or pharmacological toxicity of GM-CSF due to the species specificity of GM-CSF. In mice and rabbits, the repeated i.m./i.d. administration of the vaccine did not result in any systemic toxicity, nor were there any deaths attributed to the administration of the vaccine, or adverse effects on ophthalmology, lesions at necropsy, body weight parameters, or food consumption (data not shown).
In the mice, a sporadic and very slight erythema was observed at both the intradermal and intramuscular injection sites in a small number of animals, including the vehicle controls. These findings appeared to be coincidental to the injection procedure and not associated with the vaccine, because of the presence in the vehicle controls. Edema was not observed at any time-point in the mice throughout the study (data not shown). In the rabbits, erythema, (ranging from slight to well defined) and a very slight edema that appeared to increase in incidence in the vaccine-treated animals when compared with the controls was observed at the injection sites (data not shown). In general, the irritation at the injection sites was mild and occurred sporadically with the longest time interval of 4 consecutive days and was not considered to be an adverse effect of the vaccine.
Toxicity was also evaluated by clinical pathology analysis at various time-points throughout the studies. There were no statistically significant changes observed for any of the hematology or clinical chemistry parameters for the mice (data not shown). In the rabbits, the only statistically significant change in hematology parameters was noted as an increase in nucleated red blood cells in the vaccine treated animals at day 63 (data not shown). A few changes were noted in some of the clinical chemistry parameters in the rabbits (Table 2 ). However, as these statistically significant differences did not occur consistently over time, were not of a magnitude that was biologically meaningful, and were not associated with any abnormal histopathology (discussed below), they were not adversely associated with the administration of the vaccine.
A full screen of tissues from all of the animals were examined microscopically for histopathology 48 h after the final dose and at the end of each study. A summary of the histopathology findings from the mouse study for the high-dose mGM-CSF, no mGM-CSF, and the vehicle control groups is presented in Table 3 . In the mice, the only histologic change that appeared to be associated with administration of the vaccine was lymphoid hyperplasia of the bronchial-associated lymphoid tissue 
Rabbits received repeat i.m./i.d. injections of the MuSTDO 5 vaccine as described in the Materials and methods section. Serum samples were collected at the indicated time-points and analyzed for clinical chemistry. CA, calcium, BUN, urea nitrogen; A/G, albumin/globulin ratio; ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; GGT, ␥-glutamyl transpeptidase; Na, sodium, K, potassium, Cl, chloride; Chol, cholesterol; CK, creatine phosphokinase. Asterisk, a statistically significantly difference from sexmatched control value using ANOVA, PϽ 0.05; -, not statistically significant from sex-matched control.
(BALT) in the lung observed at the end of study (day 89) necropsy. The lymphoid hyperplasia of the BALT was present in one or more animals from each group, but occurred with greater frequency in groups receiving the vaccine compared with control mice, with the most lesions observed in those animals receiving mGM-CSF. Minimal to mild lymphoid hyperplasia in the BALT was identified in five of ten (high-dose mGM-CSF), five of ten (low-dose mGM-CSF, data not shown), two of ten (no mGM-CSF) and one of ten (vehicle control) animals. This lesion was characterized by an increase in the size and cellularity of lymphoid aggregates adjacent to bronchioles. The presence of mild lymphoid hyperplasia in the BALT in one of the vehicle control animals implies that nonspecific immune stimulation may be involved in the development of this alteration. However, the increased frequency of lymphoid hyperplasia in BALT in animals that received the MuStDO 5 vaccine with or without mGM-CSF pDNA suggests that the administration of one or more of the plasmids may have contributed to lymphoid proliferation in the lung. Other lymphoid organs had a scattered incidence of lymphoid hyperplasia, but there were no dose-related trends in the pattern of occurrence. Importantly, none of the the adverse pathology associated with GM-CSF such as overaccumulation of macrophages in tissues, retinal problems, and muscle wasting that have been observed in transgenic mice that overexpress mGM-CSF were observed in any of the mice. 37 In the rabbits, no adverse histological findings were observed that could be attributed to the administration of the vaccine (Table 4 ). The lesions noted during the microscopic evaluation of the tissues were considered to be incidental because of their random appearance in the Table 3 control and vaccine-treated groups. Furthermore, none of the findings could be correlated with any other systemic effects. In general, the histologic findings represented incidental lesions commonly seen in this species including pleocellular or mononuclear cell infiltrates in numerous organs, cysts in the thyroid and parathyroid, mineralization in organs, such as the ovaries and lymphoid tissue of the cecum, and intestinal parasites. Because of a theoretical concern for the induction of an adverse inflammatory response at the site of injection as a result of the administration of a vaccine encoding foreign antigens as well as GM-CSF, the injection sites (muscle Gene Therapy and skin) were carefully analyzed for any abnormal histopathology. None of the findings at the injection sites were considered to be adversely related to the administration of the vaccine. In mice at the early time-point (day 27), mixed cell inflammation (comprised of various admixtures of macrophages, lymphocytes, plasma cells and granulocytes) and myofiber degeneration was observed with equal frequency at the intramuscular site in both the vaccine and control-treated groups. At the dermal injection site, mixed cell inflammation (predominantly lymphocytes with occasional granuloctyes) or mononuclear cell inflammation (lymphocytes with occasional macrophages) was observed in the subcutaneous tissue underlying the skin at the same timepoint (day 27). These changes were present mainly in the groups that received the vaccine, suggestive of a vaccinerelated effect. However, the minimal to mild severity, low incidence, and similarity to the inflammatory lesions noted at the intramuscular injection site were consistent with an effect of the injection procedure and was not considered to be adversely related to the administration of the vaccine. At the end of the study, the findings at the intramuscular site of injection in the mice consisted of sporadic mixed cell inflammation, regeneration of the myofiber, and minimal degeneration of the myofiber that occurred with equal frequency in all of the groups including the controls. The presence of regeneration and the relative absence of degeneration and inflammation were consistent with repair and recovery from injection-associated lesions noted at the intramuscular injection site in animals at the earlier time-point. There were no histological findings at the intradermal injection site at this timepoint.
In the rabbits, minimal changes at the dermal and intramuscular injection sites were seen in small numbers of animals in all groups, including the control group at the early time-point (day 37). These changes were con-sidered to be related to the injection procedure and not to the vaccine. The changes included infiltrates of mononuclear cells or a pleocellular infiltrate (mixed mononuclear cells plus heterophils) in the dermis and/or muscle; occasional hemorrhage and rare fibrosis; and myodegeneration or degeneration (muscle) and loss of hair follicles. At the end of the study (day 67), no histological findings were noted at the intramuscular site of injection for any group and the sporadic findings noted at the intradermal site of injection; follicular degeneration, hemorrhage of the subcutaneous muscle, and subcutaneous hemorrhages were not considered to be adversely related to the administration of the vaccine.
The safety analysis of a pDNA vaccine expressing a foreign protein or cytokine must take into consideration the potential for the development of an aberrant immune response and subsequent immune-mediated pathology. Thus, in these studies, the histopathology analysis included PAS staining of the kidneys to visualize immune complexes. Furthermore, the lung, eye, and stifle joint were also examined for evidence of an inflammatory response that could be indicative of autoimmune disease. All of these tissues were found to be normal in both species without any histomorphological changes indicative of any immune mediated pathology (Tables 3 and 4 ). In the mice, thickening of the glomerular loops was observed in the PAS-stained kidneys of two of the vaccine-treated females (one in the low-dose mGM-CSF and one in the no-mGM-CSF group at the end of study, day 89 histopathology analysis). This finding was not considered to be indicative of an adverse toxicological effect or an indication of autoimmune disease as it was only observed in two animals. Moreover, it was not severe and was not accompanied by any other findings indicative of adverse toxicity or autoimmune pathology.
As another indicator of immune pathology, the serum from the vaccine-treated animals was assayed for antinuclear antibodies (ANA) and antibodies to dsDNA. As a positive control, serum from age-matched MRL/MpJ mice was included as this strain of mice develops an autoimmune disease analogous to lupus characterized by the production of autoantibodies including antibodies to dsDNA. 38 The repeated administration of the vaccine did not have any effects on the titers for antibodies to dsDNA or ANA in either the mice or rabbits. In the mice, the individual anti-dsDNA antibody titers for the vaccinetreated groups ranged from 0.49 to 5.25 IU/ml and were not significantly different from vehicle control groups (Table 5) . Furthermore, no increase in the anti-dsDNA antibody titers was observed in the vaccine-treated groups with time (ie day 27 versus day 89). In contrast, in the positive control MRL/MpJ mice, the individual titers for antibodies to dsDNA ranged from 1.73 to 444 IU/ml, with the majority of the animals having titers greater than 20 IU/ml by day 89. In the rabbits, the predose values for antibodies to dsDNA for the vaccine treatment groups ranged from 1.23 IU/ml to 1.78 IU/ml, while the post-dose values ranged from 0.94 IU/ml to 1.60 IU/ml.
With regard to ANA titers, the majority of the mice in the vaccine-treated and vehicle-treated groups had ANA titers of 0-2 (negative to moderately reactive) that did not increase with time (day 37 versus day 89), with the exception of two females in the no-mGM-CSF group that had ANA titers of 3 on day 89 (strongly reactive) and Gene Therapy one female in the vehicle group that had an ANA titer of 4 on day 89 (very strongly reactive). In the positive control MRL/MpJ mice, all of the animals had ANA titers of 4 (very strongly reactive) by day 89. Thus, in a few instances, individual assay values for ANA reactivity in animals appeared elevated, but the incidence was similar in vehicle-treated animals and test article-treated animals and thus was not attributed to the administration of the test article. Likewise, in the rabbits the pre-dose levels for ANA for the vaccine treatment groups ranged from 0 to 2 and the post-dose values also ranged between 0 and 2 with the exception of one female in the MuStDO 5-hGM-CSF group that had an ANA value of 3 at day 37.
Discussion
Malaria is a serious health problem with global implications for which there is no effective vaccine. In the studies described herein, the safety of a multicomponent pDNA vaccine, MuSDTO 5, comprised of five pDNAencoding malaria proteins and one pDNA encoding the cytokine, GM-CSF, has been evaluated. This vaccine will be the first multicomponent pDNA-based vaccine to be administered to healthy volunteers who will go on to be challenged with an infectious dose of P. falciparum, the causative agent of malaria. These studies represent the first report of a detailed safety and pharmacological analysis of a pDNA-based vaccine that includes a cytokine-encoding pDNA. The human GM-CSF pDNA was included in the vaccine to increase the immunogenicity as GM-CSF is known to attract dendritic cells to the site of administration and enhance the maturation of dendritic cell precursors which play an important role in antigen presentation. [19] [20] [21] [22] [23] [24] While co-administration of GM-CSF pDNA has been demonstrated to enhance the immunogenicity of pDNA vaccines, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] the overexpression of GM-CSF in transgenic mice has been demonstrated to result in adverse pathology associated with overaccumulation of macrophages in tissues, accumulation of macrophages in the peritoneal and pleural cavities, retinal damage, muscle wasting, and a fatal tissue damage syndrome. 37 Thus, the inclusion of GM-CSF in the vaccine raised several important theoretical safety concerns which had to be addressed before the vaccine could be taken into a clinical trial with healthy volunteers.
The serum and muscle expression of GM-CSF was evaluated in pharmacology studies in mice. GM-CSF could not be detected in the serum even after repeat administration of the MuStDO 5-mGM-CSF vaccine. This finding may not be surprising given the relatively short half-life of GM-CSF in mice (approximately 21 min), 39 presumably due to its rapid clearance by receptormediated uptake in mice. 40 Thus, due to the short serum half-life of GM-CSF, serum levels of GM-CSF may be a misleading index for the occurrence or nonoccurrence of GM-CSF expression following pDNA administration. In our studies, GM-CSF may have been expressed in the serum at biologically active levels, but below the limits of detection of our ELISA system (2 pg/ml) due to rapid uptake and clearance by the endogenous receptors.
In contrast to the serum, GM-CSF was readily detected in the muscles as early as 6 h (the earliest time-point evaluated) following a single dose of the MuStDO 5-mGM-CSF vaccine. Similar results demonstrating muscle 
ANA Female Male
Day 27 4 ± 0 4 ± 0 Day 89 4 ± 0 4 ± 0 Animals received repeated i.m./i.d. injections of the MuSTOD 5 vaccine as described in the Materials and methods section. Serum samples were collected from the mice on days 27 (48 h after the final injection) and 89 (end of study) and from the rabbits pre-dose and on days 37 (48 h after the final injection) and 63 (end of study). The data are reported as the average titer ± the standard deviation. The anti-dsDNA titer is reported as IU/ml. ANA results are reported as the reactivity to each pool; 0 = negative; 1 = weakly reactive; 2 = moderately reactive; 3 = strongly reactive; 4 = very strongly reactive.
expression, but undetectable serum levels of a cytokine, have been reported in mice using a pDNA encoding an IL-4/IgG1 chimeric protein. In these studies, the chimeric IL-4/IgG1 protein was readily detected in the muscle but could not be detected in the serum of any of the mice following intramuscular administration of the IL-4/IgG1 encoding pDNA. 41 In animals that received the MuStD0 5-mGM-CSF vaccine, muscle GM-CSF expression peaked at 2 days after administration, then rapidly declined to approximately 1% of the peak by day 10 after administration, and could no longer be detected by day 14 after administration. The administration of GM-CSF pDNA plus control pDNA (backbone vector lacking the malaria antigen coding sequences), or GM-CSF pDNA alone, resulted in similar early pharmacokinetics with expression peaking at 1-3 days after administration. However, while GM-CSF was undetectable 14 days after administration of the MuStDO 5-mGM-CSF vaccine, administration of GM-CSF pDNA alone or in combination with control pDNA resulted in GM-CSF levels at 20% of the peak expression by day 14 and was still detected as late as 28 days after administration, the latest time-point evaluated in these studies.
These results suggest that intramuscular administration of a pDNA encoding a self-cytokine such as GM-CSF, can lead to stable expression. In contrast, the coadministration of pDNA encoding foreign antigens, such as the malaria proteins in the MuStDO 5 vaccine, combined with a pDNA encoding GM-CSF, resulted in relatively short-term expression of GM-CSF, possibly due to an immune response against the P. falciparum proteins that non-specifically eliminated the GM-CSF plasmid in those cells co-expressing the foreign malaria proteins. This short-term expression of GM-CSF would be sufficient to augment the immune response to the malaria antigens, but would not persist long enough to cause any adverse pathology, which in part, may explain the lack of GM-CSF toxicity in the mouse safety study.
The tissue distribution of the MuStDO 5 vaccine was also evaluated in mice using real-time Taqman PCR analysis, employing primers specific for backbone sequences common to all six plasmids. While we have previously determined the tissue distribution of a monovalent (single pDNA) malaria pDNA vaccine following intramuscular administration, 43 this early study did not employ quantitative PCR and only gave a qualitative esti-mate as to the plasmid load in each tissue. In contrast, the study described herein allowed us to quantitate the amount of plasmid in each tissue following a combined i.m./i.d. administration of a multivalent pDNA vaccine. At 48 h after administration, pDNA was readily detected in all of the tissues examined, with the exception of the gonads, with the highest levels being found at the sites of injection. By 7 days after injection, the muscle and dermis contained the most plasmid with pDNA being detected at low levels in the majority of the peripheral tissues. As the animals in this study were not perfused before necropsy, the presence of plasmid in the peripheral tissues at the early time-points was most likely due, in part, to residual plasmid in the blood, as pDNA was detected in the blood in the majority of animals at these time-points. By 4 weeks after administration, the amount of pDNA was reduced with the majority being found in the muscle and only very low levels detected sporadically in some of the peripheral tissues. The pDNA was found to persist in the muscle for up to 8 weeks. In this study, we found that the amount of pDNA in the dermis tissue was difficult to quantitate due to inhibition of the PCR assay. Plasmid DNA was only detected in the gonads of two animals at one time-point. It was detected at low levels and attributed to residual plasmid in the blood and not due to specific retention of pDNA by the gonads.
The results from this analysis indicate that the majority of the pDNA was cleared by 4 weeks with low levels remaining only at the sites of injection. These results are consistent with our previous tissue distribution study with the monovalent malaria vaccine. 43 Thus, regardless of the route of administration, (ie i.m. versus i.m./i.d.), or the valency of the vaccine (ie monovalent versus multivalent), pDNA is rapidly cleared from peripheral tissues and persists at low levels at the site of administration.
Finally, the MuStDO 5 vaccine was evaluated for safety and toxicity in mice and rabbits. Due to the species specificity of GM-CSF, a pDNA encoding murine GM-CSF was used in the mouse safety study to evaluate any potential toxicity associated with the biological and/or pharmacological activities of mGM-CSF. In the rabbit study, the actual clinical vaccine product, comprised of a pDNA encoding human GM-CSF, was used to evaluate the potential toxicity of the pDNA itself and any toxicity inherent in the hGM-CSF protein expressed by the hGM-CSF encoding pDNA. The repeated i.m./i.d. administration of the MuStDO 5-mGM-CSF vaccine in mice, or the MuStDO 5 vaccine in rabbits, at doses up to 350-fold (mouse) or 7.5-fold (rabbit) over the highest proposed human dose, did not result in any toxicity. No adverse effects were observed for survival, ophthalmology, gross lesions at necropsy, body and organ weight parameters, histopathology, or clinical chemistry and hematology. A few sporadic statistically significant changes were observed in some parameters in both the mice and rabbits. However, most of the observed changes in the vaccine-treated groups were either transient, within the normal range for the species, or could not be correlated with any histopathology and were considered to be incidental, and thus not attributable to the administration of the vaccine. Furthermore, no significant differences were observed in either species between the animals which received the MuStDO 5 + GM-CSF versus those which received the MuSDTO vaccine without the GM-CSF pDNA, demonstrating the safety of the repeat administration of the GM-CSF pDNA component of the vaccine.
The only finding from the safety studies that appeared to be associated with administration of the MuSDTO 5 vaccine was lymphoid hyperplasia of the bronchial-associated lymphoid tissue (BALT) in the lung that was observed in the mouse study. While the lesion was present in one or more animals from each group, it occurred with greater frequency in those groups receiving the MuStDO 5 vaccine compared with the vehiclecontrol mice. The increased lymphoid hyperplasia in the lungs was not considered to be an adverse toxicological effect, as it did not appear to be deleterious to the overall health status of the animals. Other lymphoid organs had a scattered incidence of lymphoid hyperplasia, but there were no dose-related trends in the pattern of occurrence. Lymphoid hyperplasia of the BALT was not observed in the lungs of any of the rabbits.
Importantly, none of the adverse pathology associated with GM-CSF such as overaccumulation of macrophages in tissues, retinal pathology, accumulation of macrophages in the peritoneum and pleural cavities, muscle wasting, or death that have been observed in transgenic mice that overexpress mGM-CSF, were observed in any of the animals in the mouse safety study. 37 Furthermore, in both the mice and rabbits, the repeated administration of the vaccine did not result in any increases in ANA or antibodies to dsDNA, and no indications of autoimmune pathology were observed in any of the organs on histopathology analysis. Collectively, these findings indicate that the repeat administration of the MuStDO 5 vaccine did not result in any aberrant immune pathology.
In summary, the repeat administration of the MuStDO 5 vaccine was found to be safe and well tolerated in mice and rabbits, plasmid DNA was cleared from peripheral tissues, persisting at low levels at the site of administration, and GM-CSF protein could only be detected transiently in the muscle. The few changes noted in the safety studies were considered to be incidental and not attributable to the vaccine. These preclinical studies lay the foundation for a phase I/II clinical trial wherein healthy volunteers will receive the MuStDO 5 vaccine followed by a challenge with live P. falciparum.
Materials and methods
Plasmid DNA The MuStDO 5 vaccine is comprised of five malaria protein encoding plasmids, VCL-2510 (circumsporozoite protein, PfCSP), VCL-2519 (sporozoite surface protein-2, PfSSP2), VCL-2523 (exported protein-1, PfEXP1), VCL-2551 (liver stage antigen-1, PfLSA1), VCL-2556 (liver state antigen-3, PfLSA3), and VCL-1723 (human GM-CMSF, hGM-CSF). The malaria plasmids were constructed by cloning the P. falciparum (clone 3D7) PfCSP, PfSSP2, PfEXP1, PfLSA1, and PfLSA3 coding sequences into the eukaryotic expression vector VR-1020. 42, 44 For the mouse pharmacology and GLP safety study, the MuStDO 5 vaccine was comprised of the five malaria plasmids plus a plasmid DNA encoding murine GM-CSF (MuStDO 5-mGM-CSF). The murine (VCL-1701) and human GM-CSF (VCL-1723) encoding plasmids were prepared by cloning the respective GM-CSF coding sequences into the eukaryotic expression vector VR-1012. 45 The VR1055 plasmid used as a control in the GM-CSF pharmacology study is similar to VR1012 except that the bovine growth hormone 3ЈUTR/poly A sequence in VR1012 was replaced by a highly modified 3Ј UTR from rabbit ␤-globin.
46
Plasmid DNA was prepared by bacterial fermentation and purification, and quality assurance analysis was performed as previously described. 43, 47 Plasmid DNA was resuspended in phosphate buffered saline vehicle (PBS, 10 mm NaH 2 PO 4 , pH 7.2, 0.9% NaCl) at the desired concentration and stored at −20°C until use.
mGM-CSF pharmacology study in mice Two mGM-CSF pharmacology studies were conducted in mice. The first study was conducted at Sierra Biomedical (San Diego, CA, USA) in general compliance with the US FDA GLP Regulations currently in effect (Code of Federal Regulations, Part 58, Title 21) with the exception that an independent quality assurance unit was not involved. In this study, the MuStDO5 vaccine comprised of 20 g of each of the malaria plasmids plus 20 g of murine GM-CSF (mGM-CSF) pDNA, was administered as eight repeat i.m./i.d. injections (120 g of total pDNA/dose) to 20 CD-1 mice (10 males and 10 females, Harlan-Sprague Dawley, San Diego, CA, USA), twice a week for 4 consecutive weeks. At each of the eight treatments, the dose was split equally into two injections, 50 l intramuscular and 50 l intradermal (right dorsal surface). An additional group of 20 CD-1 mice (10 males and 10 females) received a similar administration of the PBS injection vehicle and served as the controls. Blood samples were collected for serum mGM-CSF analysis pre-dose and on days 13, 27, (48 h after final dose), 41, 55, 69, 83, and 89 (end of study), and on days 27 and 89 for anti-murine GM-CSF antibody analysis. Twenty animals (five/sex/group) were removed from study on day 27 and the remaining 20 animals (five/sex/group) were maintained on study for an additional 9-week treatmentfree period and were terminated on day 89. The serum samples were analyzed for mGM-CSF using the murine GM-CSF ELISA (R&D Systems Quantikine M mouse GM-CSF ELISA, catalogue No. MGM00, Quantitative Colorimetric Sandwich ELISA; Minneapolis, MN, USA). The serum samples were analyzed for antibodies to mGM-CSF using an ELISA that employed recombinant mGM-CSF (Cedarlane, CL9300R) to coat the plates and alkaline phosphatase conjugated goat anti-mouse IgG (H+L) AP (BioRad 170-6520) or goat anti-rabbit IgG (H+L) AP (BioRad 170-1063) were used as the detecting antibodies. Rabbit anti-mGM-CSF IgG (Cedarlane CL9165AP; Ontario, Canada) and a mouse anti-mGM-CSF antibody (provided by David Weiner, University of Iowa) obtained from mice hyperimmunized with a GM-CSF/38C13 fusion protein (mouse B cell lymphoma idiotype expressed on the murine 38C13 tumor) were used as the positive controls in the assay. Normal mouse serum was used as the negative control.
In the second study conducted under standard laboratory practices at Vical, Inc., the MuStDO5 vaccine, comprised of 20 g of each of the malaria plasmids plus 20 g of the mGM-CSF plasmid, was administered as a single i.m. injection (120 g of total pDNA/dose) to female BALB/c mice (eight mice/time-point, Harlan-Sprague Dawley, San Diego, CA, USA) in a 50 l volume in PBS injection vehicle. Control groups of female BALB/c mice (eight muscles/time-point) received i.m. injections of 20 g/muscle of the mGM-CSF pDNA alone, 20 g of the mGM-CSF pDNA + 100 g of control plasmid DNA, or MuStDO 5 without GM-CSF pDNA (20 g of each malaria pDNA) + 20 g VR1055 (control pDNA) in a 50 l volume in PBS vehicle. Blood samples were collected for serum and the injected muscles were collected for mGM-CSF analysis at 6 h and 1, 2, 3, 7, 10, 14, 21 and 28 days after pDNA administration. Serum was stored at −70°C for mGM-CSF ELISA analysis.
Quadriceps muscles were collected and immediately frozen on dry ice in 1.5 ml microcentrifuge tubes and then stored at −70°C until processing. For processing, muscle samples were pulverized and extracted as previously described. 48 Each muscle sample was extracted into a 1 ml final volume. The samples were then tested in duplicate in the mGM-CSF ELISA.
Tissue distribution in mice This study was conducted at BioReliance (Rockville, MD, USA) under standard laboratory practices. A real-time Taqman quantitative PCR assay specific for the detection of the MuStDO 5 vaccine pDNA sequences was developed using a cocktail, VCL-PC, containing equal amounts of the malaria and human GM-CSF plasmids, to be able to specifically detect less than 100 copies of the pDNA sequences in the presence of 1 g of mouse genomic DNA. Real-time PCR conditions were optimized with regard to primers and probe concentration, dNTPs and Mg ++ concentration, and cycling conditions in an ABI Prism 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA). Optimized conditions were as follows: 1 × Universal TaqMan buffer containing AmpErase UNG and Amplitaq Gold DNA polymerase, dNTPs with dUTP (PE Applied Biosystems), 0.85 m each primer (described below), 120 nm probe and 1 g genomic DNA in a final volume of 50 l. Amplification was performed with the following cycling conditions: 50°C × 2 min (one cycle); 95°C × 10 min (one cycle); 95°C × 15 s, 60°C × 1 min (40 cycles).
The assay was found to have a limit of detection of 10 copies/g of genomic DNA and was linear over a template range spanning from 10 to 10 4 copies. Because of the Poisson distribution effects during sampling, values below 10 copies could not be reliably detected. 49 Therefore, values between one and 10 copies were scored as non-quantifiable and considered to be negative. Genomic DNA was isolated using the Promega Wizard Genomic DNA purification kit. DNA was quantitated by absorbance at 260 nm and stored below −15°C. On the day of analysis, DNA stocks were diluted with sterile nuclease-free water to a final concentration of 0.2 g/l for use. Dilutions were not made on samples that had a stock concentration less than 0.2 g/l and these samples were tested neat. Five microliters of each sample was tested in the PCR reaction.
PCR analysis was performed using forward and reverse primers common to all six plasmids. The sequences for the forward primer VI-1406F (5Ј TGG GAT CTC CAC GCG AAT 3Ј, corresponding to nt 1406-1423 in the CMV promoter region), and the reverse primer VI-1475R (5Ј AGA AGC TCC GCC GCT ACC 3Ј, corresponding to nt 1458-1475 in the CMV promoter region) were selected using the Primer Express Primer Design software (PE Applied Biosystems). These primers yield an amplification product of 69 base pairs. The internal fluorogenic probe VI-1425P (5Ј CCA TGT CCG GAA CAC GTA CCC GA 3Ј) was also selected using the Primer Express program and was labeled with the 6-FAM reporter dye (PE Applied Biosystems).
PCR reactions were performed in a 96-well plate format. Each plate included a 'no DNA' control reaction to verify the absence of reagent contamination, and two series of 10-fold template dilutions of the VCL-PC cocktail (10 1 -10 4 total copies) to generate the standard curves. Each PCR amplification was performed in duplicate on 1 g of genomic DNA. One of the duplicates was spiked with 10 2 copies of VCL-PC to verify the absence of PCR inhibitors in the DNA sample. The presence of target sequence was determined by a PCR amplification yielding a fluorescent signal (C t ) that rose above the baseline threshold before the final cycle (cycle 40).
For each assay, the set of PCR reactions was considered valid and free of contamination if the no DNA control had a C t = 40, and if at least three of the plasmid standard dilutions produced C t values Ͻ40. For each tissue sample, an individual PCR reaction was considered informative if the corresponding spiked control produced a C t Ͻ40. A C t = 40 in a spiked sample indicated that the PCR reaction was inhibited, and the test for that sample was considered non-informative (NI). An informative PCR reaction was considered negative if the unspiked test sample produced a C t = 40. An informative PCR reaction was considered positive if the unspiked sample produced C t Ͻ40. The ABI 7700 instrument performed quantitations of positive samples by plotting the unspiked sample on the standard curve. Samples with values greater than 10 copies were within the linear range of the VCL-PC standard curve and were considered positive.
Repeat dose safety study in mice The repeat dose study in mice was conducted at Sierra Biomedical pDNA) plus 20 g, 2 g or 0 g of the mGM-CSF plasmid. These additional four groups served as a satellite group and were used only for the analysis of antibodies to nucleic acids (ANA) and antibodies to dsDNA on days 27 and 89. MRL/MpJ mice (10 males and 10 females, Jackson Laboratories, Bar Harbor, ME, USA) were used as positive controls for the anti-dsDNA antibody and ANA assays. Five males and five females from each group were removed from study 48 h following the final vaccine administration (terminal necropsy, day 27) while the remaining mice continued on study, untreated, for an additional 9 weeks and served as the recovery group (recovery necropsy, day 89).
Animals from the main study and control groups were observed twice daily for clinical signs of toxicity, morbidity and mortality. Animals were monitored for weight and food consumption on a weekly basis. An ophthalmic examination was conducted by a board-certified veterinary ophthalmologist on each main study and control group animal before dosing and again within 48 h of each of the necropsies. The injection sites were shaved and examined approximately 24 h before the first injection to ensure that the injection site was free of lesions. Further examinations were done for the main study and control groups on the first day of dosing and on a daily basis thereafter.
The injection site was scored using a modified Draize scoring system for erythema eschar, and edema as previously described. 43 All main study and recovery animals were shaved weekly at the injection site to facilitate accurate scoring. At each of the respective necropsies on days 27 and 89, animals from the main study and control groups were analyzed for clinical chemistry, hematology, gross necropsy (including organ weights), and microscopic histopathology. Animals from the satellite and the MRL/MpJ groups were necropsied on days 27 and 89 and serum was screened for anti-dsDNA antibodies and ANA in an ELISA based assay by Ani-Lytics Inc. (Gaithersburg, MD, USA) as previously described. 43 A complete histopathological evaluation was performed on tissues from all animals from the main study and control groups according to Good Laboratory Practice (GLP) conditions at Sierra Biomedical. Tissues were fixed and preserved in 10% neutral buffered formalin, embedded in paraffin, stained with hematoxylin and eosin and evaluated microscopically. Duplicate sections of PASstained kidneys were also evaluated for basement membrane thickening.
Repeat dose safety study in rabbits The repeat dose study in rabbits was conducted at Sierra Biomedical, in compliance with the FDA GLP Regulations as set out in Title 21 of the US Code of Federal Regulations, Part 58. Two groups of eight male and eight female rabbits (15 to 19 weeks of age, Western Oregon Research, Philmath, OR, USA) were treated once weekly for 6 consecutive weeks with MuStDO 5 vaccine. Each dose was administered as 200 l via the im route and 2 × 50 l via the i.d. route. One treatment group received a vaccine comprised of 375 g of equal amounts (75 g each) of the malaria plasmids, plus 75 g of the human GMCSF pDNA. A second treatment group received 375 g of the MuStDO 5 vaccine without the hGM-CSF pDNA. The cumulative dose for the rabbits was 6.5-7.5 greater than the highest proposed human dose on a mg/kg basis. An additional group of eight rabbits/sex received the PBS injection vehicle at the same volume and treatment regimen and served as the controls.
The animals were observed daily for morbidity and mortality. Body weights were determined on days −1, 6, 13, 27, 30, 34, 41, 48, 55 and 62. The injection sites were shaved and examined approximately 24 h before the first injection to ensure that the injection site was free of lesions. The injection sites were subsequently analyzed daily for lesions and scored using the modified Draize system. 43 The injection sites were shaved weekly to facilitate accurate scoring. All animals were examined by indirect opthalmoscopy by a board-certified veterinary ophthalmologist before the study and within 48 h of the scheduled necropsies on day 37 and 63 (end of study). Blood samples for evaluation of serum clinical chemistry and hematology were collected via an ear artery from all animals before the study and at 2-week intervals until termination on days 0 (pre-treatment), 14, 28, 37, 42, 56 and 63. In addition, serum samples were analyzed for ANA and antibodies to dsDNA pre-dose and on days 37 and 63. Four animals per sex from each group were removed from study 48 h following the final DNA administration (day 37) and the remaining four/sex/group served as the recovery group and were kept on study for an additional 4-weeks, treatment-free and were terminated on day 63. At each of the scheduled necropsies, a complete necropsy was performed on each animal and selected tissues were collected, weighed and subjected to microscopic histopathological evaluation.
A complete histopathological evaluation was performed on tissues from all animals from the main study and control groups according to GLP conditions at Sierra Biomedical. Tissues were fixed and preserved in 10% neutral buffered formalin paraffin embedded, stained with hematoxylin and eosin, and examined microscopically. Duplicate sections of PAS-stained kidneys were also evaluated for basement membrane thickening.
Statistical analysis
Statistical analysis of data was performed at the 0.05 level of significance using ANOVA for analysis of variance and Dunnett's t test for comparison of differences between group mean values using SAS Version 7.0. Data were initially analyzed as a fully crossed three-way ANOVA with sex, time and group as the factors. When a significant value was observed, Dunnett's adjusted contrasts were performed to locate the groups which differed from the controls.
